BlossomHill Therapeutics (BLSM) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on small molecule medicines for cancer treatment.

• Lead programs: BH-30643 (OMNI-EGFR inhibitor for EGFR-mutant NSCLC), BH-30236 (CLK inhibitor for R/R AML and HR-MDS), and preclinical BH-501284 (pan-KRAS inhibitor).

• Founded in 2020, based in San Diego, CA, with a team experienced in oncology drug development.

• Strategy includes advancing clinical programs, expanding pipeline, and building commercialization capabilities.

Financial performance and metrics

• Net losses: $30.7M (2024), $60.6M (2025); Q1 2026 net loss: $21.0M.

• Accumulated deficit as of March 31, 2026: $156.0M.

• Cash and cash equivalents as of March 31, 2026: $116.0M.

• No product revenue to date; operations funded by $257M in private capital.

• Existing cash plus IPO proceeds expected to fund operations into Q1 2028.

Use of proceeds and capital allocation

• Estimated net proceeds of $111.7M (or $129.1M if underwriters' option exercised) at $16.00/share IPO price.

• Proceeds to fund: $70M for BH-30643 clinical development, $20M for BH-30236, $15M for BH-501284 IND-enabling studies and Phase 1, and remainder for R&D, capital expenditures, and general purposes.

• May use a portion for strategic investments, but no current commitments.